Search research articles
Contact Us
Filters
Showing results (151-160 of 401) with videos related to
Page
of 41
Sort By:
The American Journal of Cardiology
|
February 17, 2017
Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor
Michael A Gaglia, Michael J Lipinski, Thibault Lhermusier, et al.
Platelets
|
December 28, 2020
Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy
Barry W Hennigan, Richard Good, Carly Adamson, et al.
Thrombosis and Haemostasis
|
November 8, 2005
Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor
Jon R Ward, Lynne Bingle, Heather M Judge, et al.
JAMA Cardiology
|
November 15, 2018
Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study
Daniel Lindholm, Stefan K James, Katja Gabrysch, et al.
American Heart Journal
|
April 1, 2009
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
Stefan James, Axel Akerblom, Christopher P Cannon, et al.
Platelets
|
June 2, 2021
Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy
Thomas A Nelson, William A E Parker, Tatevik Ghukasyan Lakic, et al.
European Heart Journal
|
September 30, 2015
Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study
Emil Hagström, Stefan K James, Maria Bertilsson, et al.
Lancet (London, England)
|
August 31, 2010
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
Lars Wallentin, Stefan James, Robert F Storey, et al.
Trials
|
December 8, 2016
The RAPID-CTCA trial (Rapid Assessment of Potential Ischaemic Heart Disease with CTCA) - a multicentre parallel-group randomised trial to compare early computerised tomography coronary angiography versus standard care in patients presenting with suspected or confirmed acute coronary syndrome: study protocol for a randomised controlled trial
Alasdair J Gray, Carl Roobottom, Jason E Smith, et al.
Clinical Chemistry
|
May 24, 2013
Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study
Axel Åkerblom, Lars Wallentin, Anders Larsson, et al.
Page
of 41
Search research articles
Search
Showing results (151-160 of 401) with videos related to
Sort By:
Page
of 41
The American Journal of Cardiology
|
February 17, 2017
Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor
Michael A Gaglia, Michael J Lipinski, Thibault Lhermusier, et al.
Platelets
|
December 28, 2020
Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy
Barry W Hennigan, Richard Good, Carly Adamson, et al.
Thrombosis and Haemostasis
|
November 8, 2005
Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor
Jon R Ward, Lynne Bingle, Heather M Judge, et al.
JAMA Cardiology
|
November 15, 2018
Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study
Daniel Lindholm, Stefan K James, Katja Gabrysch, et al.
American Heart Journal
|
April 1, 2009
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
Stefan James, Axel Akerblom, Christopher P Cannon, et al.
Platelets
|
June 2, 2021
Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy
Thomas A Nelson, William A E Parker, Tatevik Ghukasyan Lakic, et al.
European Heart Journal
|
September 30, 2015
Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study
Emil Hagström, Stefan K James, Maria Bertilsson, et al.
Lancet (London, England)
|
August 31, 2010
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
Lars Wallentin, Stefan James, Robert F Storey, et al.
Trials
|
December 8, 2016
The RAPID-CTCA trial (Rapid Assessment of Potential Ischaemic Heart Disease with CTCA) - a multicentre parallel-group randomised trial to compare early computerised tomography coronary angiography versus standard care in patients presenting with suspected or confirmed acute coronary syndrome: study protocol for a randomised controlled trial
Alasdair J Gray, Carl Roobottom, Jason E Smith, et al.
Clinical Chemistry
|
May 24, 2013
Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study
Axel Åkerblom, Lars Wallentin, Anders Larsson, et al.
Page
of 41